期刊文献+

成都市温江地区恶性肿瘤发病分析 被引量:3

Analysis of incidence of malignancies in 2007in Wenjiang,Chengdu
下载PDF
导出
摘要 目的了解温江地区恶性肿瘤发病情况,为恶性肿瘤防治提供科学依据。方法对2007年温江地区恶性肿瘤登记处收集的恶性肿瘤发病数据进行整理分析,统计主要恶性肿瘤的发病数、发病率、顺位等指标。结果 2007年温江地区恶性肿瘤粗发病率为104.9/10万,35岁后恶性肿瘤发病率呈明显上升趋势。男性发病率居前5位的依次为肺癌、肝癌、胃癌、食管癌、结直肠和肛门恶性肿瘤,女性发病率居前5位的依次为肺癌、食管癌、结直肠和肛门恶性肿瘤、乳腺癌、肝癌。结论温江地区恶性肿瘤发病率低于全国水平,男性、中老年人是发病高危人群。肺癌和食管癌、肝癌、胃癌为主的消化道肿瘤是最主要的恶性肿瘤,应进行重点防治。 Objective To know the cancer incidence situation in Wenjiang,Chengdu in 2007and provide evidence for local cancer control and prevention. Methods The data came from Wenjiang cancer registry. The incidence rate and inci- dence sequence of cancer were analyzed. Results The crude incidence rate was 104.9/100 000 in 2007. The incidence rate raised up from the age of 35. The common cancers ranked top 5 in male were lung cancer,liver cancer,stomach cancer,e- sophagus cancer and colon cancer. The common cancers ranked top 5 in female were lung cancer,esophagus cancer,colon cancer,breast cancer and liver cancer. Conclusion The malignant tumor incidence rate in Wenjiang is lower than that in the national level, in which the man and older people are high risk population. Lung cancer and esophageal cancer, liver cancer, gastric cancer of digestive tract tumor are the most primary malignancy, should be the focus of control.
出处 《西部医学》 2013年第12期1782-1784,共3页 Medical Journal of West China
基金 四川省卫生厅科研课题(110049)
关键词 恶性肿瘤 监测 发病率 流行病学 温江 Cancerl Monitoring Incidence rate Epidemiology Wenjiang
  • 相关文献

参考文献10

二级参考文献54

共引文献156

同被引文献42

  • 1Karimi P, Islami F, Anandasabapathy S, et al. Gastric cancer: de- scriptive epidemiology, risk factors, screening, and prevention [J]. Cancer Epidemiol Biomarkers Prey, 2014, 23(5): 700-713.
  • 2Bezerra DP, Pessoa C, de Moraes MO, et al. Overview of the therapeutic potential of piplartine (piperlongumine) [J]. Eur J Pharm Sci, 2013, 48(3):453-463.
  • 3Wang F, Mao Y, You Q, etal. Piperlongumine induces apopto-sis and autophagy in human lung cancer cells through inhibition of PI3K/Akt/mTOR pathway [J]. Int J Immunopathol Pharma- col, 2015, 28(3); 362-373.
  • 4Kang Q, Yan S. Piperlongumine reverses doxorubicin resistance through the PI3K/Akt signaling pathway in K562/A02 human leukemia cells [J]. Exp Ther Med, 2015, 9(4); 1345-1350.
  • 5Zhu T, Wu XL, Zhang W, et al. Glueagon Like Peptide-1 (GLP-1) Modulates OVA-Induced Airway Inflammation and Mucus Secretion Involving a Protein Kinase A (PKA)-Depend- ent Nuclear Factor-kB (NF-kB) Signaling Pathway in Mice [J]. Int J Mol Sci, 2015, 16(9): 20195-20211.
  • 6Zhu T, Zhang W, Xiao M, et al. Protective role of androgra- pholide in bleomycin-induced pulmonary fibrosis in mice [J]. Int J Mol Sci, 2013, 14(12): 23581-23596.
  • 7Ang TL, Pock KM. Clinical epidemiology of gastric cancer [J]. Singapore Med J, 2014, 55(12) : 621-628.
  • 8Venerito M, Nardone G, Selgrad M, et al. Gastric cancer-epi- demiologic and clinical aspects [J]. Helicobacter, 2014, 19(1): 32-37.
  • 9Sun LD, Wang F, Dai F, et al. Development and mechanism inves- tigation of a new piperlongumine derivative as a potent anti-inflam- matory agent [J]. Biochem Pharmacol, 2015, 95(3): 156-169.
  • 10Son DJ, Kim SY, Han SS, et al. Piperlongumine inhibits ather- osclerotic plaque formation and vascular smooth muscle cell pro- liferation by suppressing PDGF receptor signaling [J]. Biochem Biophys Res Commun, 2012, 427(2): 349-354.

引证文献3

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部